Paper Details

  1. Home
  2. Paper Details

Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice.

Author: AmpueroMario F, ClotetBonaventura, CurranAdrian, MoltóJosé, Navarro-MercadeJordi, ParedesRoger, PelaezPablo, Pérez-AlvarezNuria, SantosJosé R

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the effectiveness and safety of switching from darunavir/ritonavir to darunavir/cobicistat monotherapy in HIV-infected patients. The results showed that the switch was safe and effective in patients with well-controlled HIV infection, with a high rate of patients remaining free of treatment failure.
Paper Details　
Original Abstract of the Article :
Our aim was to evaluate the effectiveness and safety of darunavir/cobicistat (DRV/c) monotherapy as an antiretroviral treatment simplification strategy in HIV-infected patients already on suppressive darunavir/ritonavir (DRV/r) monotherapy in routine clinical practice. We conducted a retrospective m...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1089/AID.2018.0178

データ提供：米国国立医学図書館（NLM）

Simplifying Antiretroviral Treatment: A New Strategy for HIV Management

This study evaluates the efficacy and safety of simplifying antiretroviral treatment from [darunavir/ritonavir (DRV/r) monotherapy] to [darunavir/cobicistat (DRV/c) monotherapy] in HIV-infected patients already on suppressive DRV/r monotherapy. The researchers conducted a retrospective multicenter study analyzing the outcomes of patients who transitioned from DRV/r to DRV/c monotherapy while maintaining viral suppression. The study aimed to determine the effectiveness and safety of this treatment simplification strategy in routine clinical practice.

DRV/c Monotherapy: A Safe and Effective Treatment Simplification Strategy

The study's findings suggest that switching to DRV/c monotherapy appears to be safe and effective in routine clinical practice for HIV-infected patients undergoing suppressive DRV/r monotherapy. The study revealed a high rate of treatment success, with 90% of patients remaining free of treatment failure during follow-up. The study's findings highlight the potential of DRV/c monotherapy as a valuable tool for simplifying treatment regimens while maintaining viral suppression in HIV-infected patients.

Improving HIV Treatment Adherence and Quality of Life

The study's findings offer hope for HIV-infected patients seeking simpler and more convenient treatment regimens. The potential of DRV/c monotherapy to effectively maintain viral suppression while reducing treatment complexity could improve treatment adherence and enhance patients' overall quality of life. Further research is needed to optimize this treatment strategy and to evaluate its long-term impact on HIV outcomes.

Dr.Camel's Conclusion

This study, like a refreshing oasis in the desert of HIV treatment, unveils a potential path towards simplifying treatment regimens without compromising effectiveness. The study's findings offer hope for a future where HIV management is more manageable and less burdensome for patients.

Date :
  1. Date Completed 2020-07-22
  2. Date Revised 2020-07-22
Further Info :

Pubmed ID

30909716

DOI: Digital Object Identifier

10.1089/AID.2018.0178

Related Literature

Article Analysis
・Effects of darunavir and cobicistat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.